Literature DB >> 36267137

Potential Treatment for Obsessive-Compulsive Disorder.

Robert B Kargbo1.   

Abstract

Obsessive-compulsive disorder (OCD) affects approximately 2% of the population worldwide and is also prevalent in other neuropsychiatric disorders. Serotonin reuptake inhibitors have limited widespread success. Alternate treatment options for OCD and other indications are highlighted using 3-bromo-lysergic acid diethylamide. Published 2022 by American Chemical Society.

Entities:  

Year:  2022        PMID： 36267137      PMCID： PMC9578026          DOI： 10.1021/acsmedchemlett.2c00390

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


  6 in total

Review 1.  Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).

Authors:  David E Nichols
Journal:  ACS Chem Neurosci       Date:  2018-03-01       Impact factor: 4.418

Review 2.  Metabolism of lysergic acid diethylamide (LSD): an update.

Authors:  Rui Filipe Libânio Osório Marta
Journal:  Drug Metab Rev       Date:  2019-07-16       Impact factor: 4.518

Review 3.  Abnormal resting-state functional connectivity in patients with obsessive-compulsive disorder: A systematic review and meta-analysis.

Authors:  Jing Liu; Lingxiao Cao; Hailong Li; Yingxue Gao; Xuan Bu; Kaili Liang; Weijie Bao; Suming Zhang; Hui Qiu; Xue Li; Xinyue Hu; Lu Lu; Lianqing Zhang; Xinyu Hu; Xiaoqi Huang; Qiyong Gong
Journal:  Neurosci Biobehav Rev       Date:  2022-02-10       Impact factor: 8.989

Review 4.  The promises and perils of psychedelic pharmacology for psychiatry.

Authors:  Tristan D McClure-Begley; Bryan L Roth
Journal:  Nat Rev Drug Discov       Date:  2022-03-17       Impact factor: 84.694

Review 5.  The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers.

Authors:  Hang Li; Yi Zhong; Siyuan Yang; Jiahe Wang; Xiang Li; Jianguo Xu; Heng Gao; Gang Chen
Journal:  Hum Psychopharmacol       Date:  2021-11-05       Impact factor: 1.672

Review 6.  Psychedelic treatment of functional neurological disorder: a systematic review.

Authors:  Matthew Butler; Mathieu Seynaeve; Timothy R Nicholson; Susannah Pick; Richard A Kanaan; Andrew Lees; Allan H Young; James Rucker
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.